Global Market Study on Microbiome Therapeutics: United States Projected to be the Dominant Regional Market During 2018 - 2025

Microbiome Therapeutic  Market
  • Published On : Jan-2018 |
  • Pages : 144 Pages |
  • Format : Microbiome Therapeutic  Market Microbiome Therapeutic  Market Microbiome Therapeutic  Market Microbiome Therapeutic  Market

Human microbiome to have a tremendous impact on human health

Human microbiome has co-evolved with humans for centuries, which includes bacteria, viruses, fungi, Achaeans etc. The human microbiome is now one of the fastest growing areas of biology, and is considered as a newly discovered organ with the potential to have a tremendous impact on human health. Microbiome therapeutics are therapies that are designed to disrupt unhealthy microbial ecological networks and that catalyse the establishment of healthy ones. Destructive changes in the human microbiome composition, called as dysbiosis, is considered as a key factor in allergies, arthritis, asthma, autism, colon cancer, C. difficile infections, diabetes, inflammatory bowel disease, obesity and many other diseases. Currently there are no approved microbiome therapeutics available in the market and it will take a couple of years more work on candidates currently in pipeline and launch them in the market.

Persistence Market Research estimates that the global market for microbiome therapeutics is expected to surpass US$ 890 Mn by 2025 end, exhibiting an exponential CAGR of 62.9% over 2018–2025. At present there are no marketed microbiome therapeutics in the global market, however, the first drug is expected to be launched in 2018. Targeting micriobime for correction of dysbiosis is emerging as a therapeutic option for many indications including diabetes, autoimmune disorders, oncology, obesity, rate diseases, gynaecological and neonatal disorders, bacterial infections, urinary tract infections etc. among others.

Improved microbiome sequencing capabilities are likely to boost the global microbiome therapeutics market

Results from the Human Microbiome Project and other massive studies of human bacterial symbioses have drawn enormous attention from applied biomedical research organizations, which is the primary factor expected to driving the growth of global microbiome therapeutics market. Human Microbiome Project (HMP) has led to identification of 60 Mn genes, 600 microbial reference genome and sequencing of 700 metagenomes, whereas MetaHIT catalogue contains 3.3 Mn non-redundant human microbiome genes in almost every set of genes for human gut microbiome. All of this information is being used to translate microbiome science to therapeutics. Another important factor expected to speed up growth of global microbiome therapeutics market is improved microbiome sequencing capabilities. This, in turn, is expected to boost the basic research in microbiome sequencing and reveal more about diversity of microbiome, which can be applied to discover new or improved microbiome therapeutics. Huge pipeline of microbiome therapeutics with over 120 candidates in development would decide the future of microbiome therapeutics market. However, lack of clear regulatory pathways and delays in launch of microbiome therapeutics are major factors expected to hamper the growth of microbiome therapeutics market.

Global microbiome therapeutics market study, by indication

Based on indication, the global microbiome therapeutics market has been segmented into

  • Type 2 diabetes
  • Obesity
  • C. difficile Infection
  • Primary hyperoxyurea

C. difficile infection indication segment is expected to contribute highest share of over 34% by 2025. This high share is expected to be due to early launch and more number of launches of C. difficile microbiome therapeutics in the market. Some of the other indications for which active microbiome therapeutics clinical trials are going on include gastrointestinal disorders (Crohn's disease, inflammatory bowel diseases, ulcerative colitis), prevention of preterm birth, immuno-oncology, rare metabolic disorders such as phenylketonuria, urea cycle disorders, lactose intolerance, glioblastoma etc. 

Global microbiome therapeutics market study, by region

Global market for microbiome therapeutics is segmented into four key regions viz. U.S., Europe, Japan and Rest of the world (RoW). U.S. is expected to contribute highest market share of over 44% by 2025 in global microbiome therapeutics market. Early launch of new drugs in the U.S. and rapid penetration is expected to drive the growth of the U.S. microbiome therapeutics market.

This Persistence Market Research (PMR) report examines the global microbiome therapeutics market for the period 2018–2025. The primary objective of the report is to offer insights into market opportunity for microbiome therapeutics and pipeline developments in microbiome therapeutics market. The microbiome industry is at an early stage but is undergoing rapid developments in last five years. Particular microbiome therapeutics based on human intestinal microbiome are popular and numerous programs are being carried out to evaluate their therapeutic efficacy in treating or preventing gastrointestinal disorders such as C. difficile infection, ulcerative colitis, inflammatory bowel disease (IBD) etc. among others. The market for microbiome therapeutics is primarily driven by government initiatives in funding microbiome research, success of human microbiome project, need for reliable therapeutics for certain disease indications and huge pipeline of novel microbiome therapeutics.

A highly organized report for gaining maximum clarity

The report analyzes the global opportunity for microbiome based therapeutics in terms of value (US$ Mn) and forecast. The report begins with the market definition and explaining different disease indications for which microbiome therapeutics are being developed. The market view point section includes analysis of Persistence Market Research on key trends, drivers, restraints, and macro factors influencing global market. Opportunity analysis and recommendations section provided in the report allows to better equip clients with crystal clear decision making insights.

Section on venture capital provides the analysis of financing activities by venture partners in microbiome therapeutics in last 6-7 years. The section gives detailed description of venture financing along with the capital raised by various players in microbiome therapeutics market from 2011-2017. The section helps readers to gain insights into the source of financing for novel microbiome therapeutics, most of which are being developed by early stage of clinical stage biotechnology companies.

The next section of the report covers pipeline analysis of microbiome therapeutics. Pipeline analysis section provides analysis by development stage, disease indication, number of active clinical programs by therapeutic area, geographical distribution of clinical trials and analysis by product type. The section helps readers to identify potential competitors that are working on microbiome based drugs for the same therapeutic area. The section gives detailed description of over 120 clinical, preclinical and discovery programs.

The next section of the report highlights global microbiome therapeutics market potential by various indications including C. difficile infection, preterm birth & gynaecology conditions, type 2 diabetes and obesity. The section provides analysis on the bases of epidemiology and potential patient population for each of the indication mentioned and potential for microbiome therapeutics in the global market compared to currently available treatment drugs/products for each of the indication. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global microbiome therapeutics market.

Competitive landscape section is devoted to studying the competition in this novel market

In next section of the report on microbiome therapeutics market, a detailed competitive landscape is included to provide report audiences with a dashboard view, to access the key differentiators among the competitor firms. Detailed company profiles include company-specific long-term and short-term strategies, pipeline products in microbiome therapeutics, recent developments, company’s microbiome activity analysis (in terms of pipeline, disease areas, industry sectors, number of licensing activities, partnerships, acquisitions and venture capital raised since 2010).

Market Taxonomy

By Indication

  • Type 2 Diabetes
  • Obesity
  • difficile infection
  • Primary Hyperoxyurea

 By Region

  • U.S.
  • Europe
  • Japan
  • RoW

Companies covered in Microbiome Therapeutic Market Report

Company Profiles

  • Microbiome Therapeutics Inc.
  • SERES Therapeutics Inc.
  • LNC Therapeutics Inc.
  • Vedanta Biosciences Inc.
  • Enterome SA
  • Ferring B.V.
  • ViThera Pharmaceuticals Inc.
  • Second Genome Therapeutics
  • Rebiotix
  • Synlogic Inc.
  • 4D Pharma Plc.
  • Ritter Pharmaceuticals
  • AvidBiotics
  • Osel Inc.
  • OxThera AB
  • Evelo Biosciences
  • AOBiome LLC
  • Immuron Ltd.

Microbiome Therapeutic Market

Back To Top